๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Dongguan
Clinical trial register · China

Clinical Trials in Dongguan, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Sun Yat-sen University14 AstraZeneca11 Nanfang Hospital, Southern Medical University4 Akeso4 Biogen4
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Dongguan

103 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
A Study to Understand How Nerandomilast Works in People With Active Idiopathic Inflammatory Myopathies
NCT07789015Idiopathic Inflammatory Myopathies
Boehringer Ingelheim
Phase 3
270
Beijing, Chongqing, Dongguan, Guangzhou, Hefei, Luoyang, Nanchang, Nanjing
2026-11-09
Not yet open
MRG003 Plus Toripalimab Versus Toripalimab as Neoadjuvant Therapy for PD-L1-Positive, Resectable, Locally Advanced Head and Neck Squamous Cell Carcinoma
NCT07677475Head and Neck Squamous Cell Carcinoma
Dongguan People's Hospital
Phase 2
65
Dongguan
2026-08-10
Not yet open
AI-assisted Rare Disease Diagnosis
NCT07650799Rare Disorders, Rare Diseases
Peking Union Medical College Hospital
Not applicable
1,056
Beijing, Cangzhou, Changchun, Dongguan, Foshan, Guiyang, Jilin City, Kunming
2026-08-01
Recruiting
Individualized Primary Clinical Target Volume Based on Margin Expansion for Nasopharyngeal Carcinoma
NCT07661771Non-metastatic Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 3
568
Dongguan, Foshan, Guangzhou, Shenzhen, Zhongshan, Changsha
2026-07-24
Recruiting
Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity Study of Ravulizumab in Chinese Adults With Neuromyelitis Optica Spectrum Disorder (NMOSD)
NCT07557420NMOSD, Neuromyelitis Optica Spectrum Disorder
Alexion Pharmaceuticals, Inc.
Phase 3
19
Beijing, Chengdu, Dongguan, Jinan, Shanghai, Shijiazhuang, Taiyuan, Wenzhou
2026-07-20
Recruiting
A Clinical Trial of TQH3906 Capsules in the Treatment of Active Psoriatic Arthritis
NCT07406035Psoriatic Arthritis
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 2
156
Bozhou, Beijing, Chongqing, Dongguan, Guangzhou, Jiangmen, Shenzhen, Nanning
2026-07-16
Recruiting
A Study of SKB571 Combination Therapy in Participants With Non-Small Cell Lung Cancer (NSCLC)
NCT07622186Non-Small Cell Lung Cancer
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 2
150
Beijing, Chongqing, Fuzhou, Xiamen, Dongguan, Guangzhou, Guilin, Nanning
2026-07-15
Not yet open
Hexaminolevulinate Photodynamic Therapy (HAL-PDT) With Deferred Surgery Versus Surgery for High-grade Squamous Intraepithelial Lesions (HSIL)
NCT07669363Cervical Intraepithelial Neoplasia, Papillomavirus Infections
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2
230
Fuzhou, Xiamen, Foshan, Guangzhou, Shenzhen, Zhongshan, Nanning, Dongguan
2026-07-01
Recruiting
Qishen Yiqi Dripping Pills in Treatment of Chronic Heart FailUre
NCT07687186Heart Failure
Tasly Pharmaceutical Group Co., Ltd
Phase 3
636
Bozhou, Hefei, Suzhou, Beijing, Fuzhou, Lanzhou, Qingyang, Dongguan
2026-06-22
Not yet open
Artificial Intelligence for Rare Disease Diagnosis
NCT07625436Rare Disorders, Rare Diseases
Peking Union Medical College Hospital
Not applicable
150
Beijing, Cangzhou, Changchun, Dongguan, Foshan, Guiyang, Jilin City, Kunming
2026-06-20
Not yet open
A Phase I Clinical Study of AK150 in Advanced Malignant Solid Tumor
NCT07566247Advanced Malignant Solid Tumors
Akeso
Phase 1
96
Fuzhou, Dongguan, Wuhan
2026-04-30
Recruiting
Evaluate the Efficacy and Safety of ICP-488 in Subjects With Cutaneous Lupus Erythematosus (CLE) Double-blind Study
NCT07440537Cutaneous Lupus Erythematosus (CLE)
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 2
105
Hefei, Beijing, Chongqing, Fuzhou, Dongguan, Guangzhou, Shijiazhuang, Zhengzhou
2026-04-27
Recruiting
RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)
NCT07416474Non-Small Cell Lung Cancer
RemeGen Co., Ltd.
Phase 3
574
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Dongguan, Guangzhou
2026-04-03
Not yet open
Butylphthalide for Brain Edema After Endovascular Treatment
NCT07528456Acute Ischemic Stroke
Nanfang Hospital, Southern Medical University
Phase 4
100
Dongguan, Guangzhou, Heyuan, Qingyuan, Shaoguan, Haikou, Ganzhou
2026-04-01
Recruiting
Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer
NCT06768931Breast Cancer, Triple Negative Breast Cancer (TNBC), Early Stage Breast Cancer, Immunotherapy
Sun Yat-sen University
Phase 2
192
Lanzhou, Dongguan, Guangzhou, Zhanjiang, Zigong
2026-04-01
Recruiting
Radiotherapy After Prostatectomy for Node Positive Prostate Cancer
NCT07477626Prostate Cancer (Post Prostatectomy), Radiotherapy; Image-Guided, Prostate Cancer Non-Metastatic, Androgen Deprivation Therapy
Sun Yat-sen University
Phase 3
372
Dongguan, Guangzhou, Zhanjiang, Zhengzhou, Chengdu, Hangzhou, Beijing, Shanghai
2026-03-20
Recruiting
Deep Cervical Lymphatic Venous Anastomosis in the Treatment of Alzheimer's Disease (CLEAN-AD)
NCT07073066Alzheimers Disease
Beijing Tiantan Hospital
Not applicable
376
Dongguan, Guangdong, Zhengzhou, Jinan, Jining, Ningbo, Beijing
2026-03-13
Recruiting
Toripalimab Combined With Different Platinum-Based Induction Chemotherapy Regimens for Locally Advanced Nasopharyngeal Carcinoma
NCT07362979Nasopharyngeal Cancinoma (NPC)
Sun Yat-sen University
Phase 2
243
Dongguan, Guangzhou, Shenzhen, Zhanjiang
2026-03-12
Recruiting
A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus
NCT07438496Lupus Erythematosus, Systemic
Janssen Research & Development, LLC
Phase 3
600
Beijing, Changsha, Cheng Du Shi, Dongguan, Guangzhou, Hangzhou, Hefei, Jinhua
2026-03-05
Active, closed
DIEP-MDS for Risk Stratification of Flap Vascular Compromise and Failure in Breast Reconstruction
NCT07761390Breast Neoplasms, Breast Reconstruction, Postoperative Complications
Zhuliling
Observational
1,500
Xiamen, Dongguan, Guangzhou, Huizhou, Meizhou, Shantou, Shanwei, Shaoguan
2026-01-01
Recruiting
A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
NCT07276399Squamous Cell Carcinoma of Head and Neck
Janssen Research & Development, LLC
Phase 3
500
Beijing, Bengbu, Changsha, Chengdu, Chongqing, Dongguan, Guangzhou, Hangzhou
2025-12-03
Recruiting
Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOYยฎ (US-Sourced YERVOYยฎ) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma
NCT07176650Hepatocellular Carcinoma (HCC)
Shanghai Henlius Biotech
Phase 1
246
Beijing, Bengbu, Changchun, Changsha, Chengdu, Dongguan, Fuzhou, Ganzhou
2025-11-25
Recruiting
A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough - China Extension
NCT07650084Refractory Chronic Cough
GlaxoSmithKline
Phase 3
75
Leshan, Beijing, Changsha, Chengdu, Chongqing, Dongguan, Ganzhou, Guangzhou
2025-11-21
Active, closed
Reduced-dose vs Standard-dose Irradiation for Low-risk Clinical Target Volume in Nasopharyngeal Carcinoma.
NCT07201337Nasopharyngeal Cancinoma (NPC)
Sun Yat-sen University
Phase 3
700
Dongguan, Guangzhou, Shantou, Shenzhen, Zhanjiang
2025-11-17
Recruiting
Durvalumab Consolidation After Chemoradiation Therapy for Limited Stage SCLC in China
NCT07161388Limited Stage Small-Cell Lung Cancer
AstraZeneca
Observational
200
Beijing, Cangzhou, Dongguan, Fuzhou, Guangzhou, Huzhou, Jinan, Nanjing
2025-11-17
Recruiting
A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma.
NCT07258979Recurrent or Metastatic Nasopharyngeal Carcinoma
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1/2
202
Chongqing, Fuzhou, Xiamen, Zhangzhou, Dongguan, Guangzhou, Jiangmen, Shaoguan
2025-11-05
Recruiting
A Study to Assess the Effectiveness and Safety of GSK3862995B in Adults With Bronchiectasis
NCT07201051Bronchiectasis
GlaxoSmithKline
Phase 2
363
Beijing, Chongqing, Dongguan, Guangzhou, Guilin, Hangzhou, Huizhou, Jiangmen
2025-10-30
Recruiting
Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)
NCT07204275Primary Membranous Nephropathy
Vertex Pharmaceuticals Incorporated
Phase 2/3
176
Baotou, Beijing, Bengbu, Changchun, Changsha, Chengdu, Dalian, Dongguan
2025-09-30
Not yet open
PCSK9 Inhibitors in Acute Ischemic Stroke Patients Undergoing Endovascular Therapy
NCT07174375Acute Ischemic Stroke
Nanfang Hospital, Southern Medical University
Phase 2/3
478
Fuzhou, Dongguan, Guangzhou, Heyuan, Hengzhou, Haikou, Ganzhou
2025-09-15
Recruiting
Effect of Intensive Lipid-Lowering Therapy on Coronary Atherosclerotic Plaque Progression in Young and Middle-Aged Patients With Chronic Coronary Syndrome
NCT06896708Chronic Coronary Syndrome
Liu yong
Not applicable
766
Chongqing, Dongguan, Guangzhou, Shenzhen, Zhongshan, Dalian
2025-08-12
Recruiting
A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)
NCT07098338Non-Small Cell Lung Cancer
AstraZeneca
Phase 2
278
Changsha, Chengdu, Deyang, Dongguan, Fuzhou, Guangzhou, Hangzhou, Hefei
2025-08-07
Not yet open
A Phase III Clinical Study of H077 Sustained-Release Tablets Compared With Silodosin Capsules in the Treatment of Benign Prostatic Hyperplasia
NCT07146386Benign Prostatic Hyperplasia, Benign Prostatic Hyperplasia With Lower Urinary Tract Symptoms
Shanghai Huilun Pharmaceutical Co., Ltd.
Phase 3
728
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Zhangzhou, Dongguan, Shantou
2025-08
Recruiting
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
NCT06953089Solid Tumors
DualityBio Inc.
Phase 2
450
Beijing, Dongguan, Henan, Xinxiang, Hubei, Wuhan, Changsha, Xuzhou
2025-07-18
Recruiting
A Clinical Trial Evaluating Injection of TQB6411 in Subjects With Advanced Malignant Tumors
NCT07043751Advanced Malignant Tumors
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 1
216
Beijing, Dongguan, Guangdong, Guangzhou, Anyang, Zhengzhou, Wuhan, Changsha
2025-07-15
Recruiting
QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma.
NCT06749899Nasopharyngeal Cancinoma (NPC), Nasopharyngeal Cancer
Sun Yat-Sen University Cancer Center
Phase 3
580
Fuzhou, Dongguan, Foshan, Guangzhou, Zhongshan, Nanning, Guiyang, Wuhan
2025-05-04
Active, closed
Drug-durg Interaction of RAY1225 With Warfarin, Atorvastatin, Metformin and Digoxin
NCT07362030Obesity
Guangdong Raynovent Biotech Co., Ltd
Phase 1
32
Dongguan
2025-04-14
Recruiting
A Phase II Study to Evaluate HLX43 in Subjects With Recurrent/Metastatic Nasopharyngeal Carcinoma Failed or Intolerance to Second-line Therapy
NCT06839066Nasopharyngeal Carcinoma (NPC)
Shanghai Henlius Biotech
Phase 2
70
Fuzhou, Dongguan, Guangzhou, Shenzhen, Nanning, Guiyang, Wuhan, Changsha
2025-04-02
Not yet open
Study of MCLA-129 in the Treatment of Advanced Non-small Cell Lung Cancer with AGA and MET Amplification.
NCT06885840Non-Small Cell Lung Cancer
Betta Pharmaceuticals Co., Ltd.
Phase 2
100
Hefei, Lanzhou, Dongguan, Foshan, Guangzhou, Baoding, Harbin, Zhengzhou
2025-03-31
Not yet open
A Clinical Study of AK120 in Adolescents With Moderate-to-severe Atopic Dermatitis
NCT06767540Atopic Dermatitis
Akeso
Phase 3
198
Wuhu, Beijing, Chongqing, Dongguan, Guangzhou, Jiangmen, Shenzhen, Zhuhai
2025-01-23
Active, closed
Efficacy, Safety, PK, PD, and ADA of Eculizumab in Chinese Adults With NMOSD
NCT06724809NMOSD, Neuromyelitis Optica Spectrum Disorders
Alexion Pharmaceuticals, Inc.
Phase 3
21
Beijing, Dongguan, Jinan, Shanghai, Taiyuan, Wenzhou, Wuhan
2025-01-16
Recruiting
A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced and Biologic-naive Participants With Active Psoriatic Arthritis
NCT06807424Arthritis, Psoriatic
Janssen Research & Development, LLC
Phase 3
750
Beijing, Changchun, Changsha, Chengdu, Chongqing, Dongguan, Guangzhou, Guiyang
2025-01-09
Not yet open
A Clinical Study of AK120 in Adolescents With Moderate-to-severe Atopic Dermatitis (AD)
NCT06756126Atopic Dermatitis
Akeso
Phase 2
24
Dongguan, Guangzhou, Shenzhen, Changsha, Ningbo
2024-12-30
Recruiting
Safety and Efficacy of CAR-T Cell Therapy for Relapsed/refractory Neuroblastoma and Desmoplastic Small Round Cell Tumors: a Single-arm, Open-label Trial.
NCT06836505Neuroblastoma (NB), Desmoplastic Small Round Cell Tumor (DSRCT)
Sun Yat-Sen University Cancer Center
Phase 1/2
10
Guangzhou, Dongguan, Shanghai
2024-12-12
Recruiting
A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)
NCT06667908Carcinoma, Non-Small-Cell Lung
Johnson & Johnson Enterprise Innovation Inc.
Phase 2
130
Dongguan, Guangzhou, Jinan
2024-12-06
Recruiting
Umbilical Cord Blood NK Cell Therapy for High-Risk Pediatric Soft Tissue Sarcoma: Efficacy and Safety Study
NCT06848582Soft Tissue Sarcoma (STS)
Sun Yat-sen University
Not applicable
40
Guangzhou, Dongguan
2024-11-01
Recruiting
Orelabrutinib in Combination with R-CHOP for CD5-positive DLBCL Patients๏ผˆRocket Trial๏ผ‰
NCT06647940Diffuse Large B Cell Lymphoma (DLBCL)
Sun Yat-sen University
Phase 2
39
Guangzhou, Lanzhou, Dongguan, Shantou, Shenzhen, Zhaoqing, Zhuhai
2024-11-01
Not yet open
Minimal Residual Disease Guiding Adjuvant Therapy in Stage I NSCLC
NCT06709274Non-Small Cell Lung Cancer
Guangdong Association of Clinical Trials
Not applicable
342
Dongguan, Foshan, Guangzhou, Shenzhen, Nanning, Guiyang, Wuhan, Changsha
2024-11
Recruiting
Home- vs Hospital-based Care of Anti-VEGF Treatment for Diabetic Macular Edema: Non-inferiority RCT
NCT06610747Diabetic Macular Edema
Zhongshan Ophthalmic Center, Sun Yat-sen University
Not applicable
308
Dongguan, Foshan, Guangzhou
2024-10-28
Active, closed
Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN)
NCT06564142Immunoglobulin A Nephropathy
Alpine Immune Sciences Inc, A Subsidiary of Vertex
Phase 3
605
Beijing, Cangzhou, Changchun, Changzhi, Chengdu, Chongqing, Dongguan, Foshan
2024-08-30
Active, closed
Validity and Reliability of the Mastitis Symptom Severity Assessment Methods (M-Score and BISSI) in Non-Lactational Mastitis
NCT06667609Granulomatous Mastitis, Mastitis Chronic
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Observational
320
Chaozhou, Dongguan, Guangzhou, Jiangmen, Shanwei
2024-08-28
Active, closed
A Study of Dapagliflozin in Chinese Adult Patients With Chronic Kidney Disease
NCT06610526Chronic Kidney Disease
AstraZeneca
Phase 4
731
Beijing, Changchun, Dongguan, Foshan, Fuyang, Fuzhou, Ganzhou, Harbin
2024-08-23
Recruiting
Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors
NCT06535607Sub-study 1 Cervical Cancer (Volrustomig Monotherapy), Sub-study 2 Head and Neck Squamous Cell Carcinoma (Volrustomig Monotherapy), Sub-study 3 Head and Neck Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy), Sub-study 4 Esophageal Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy)
AstraZeneca
Phase 2
257
Anyang, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Dongguan
2024-08-22
Recruiting
Randomized Study of ABC-14 Regimen Compared With "3+7" Standard Induction Therapy or AB-14 for ND AML
NCT06451861Acute Myeloid Leukemia
Guangdong Provincial People's Hospital
Phase 2
240
Dongguan, Foshan, Guangzhou, Shenzhen, Zhanjiang, Zhuhai, Haikou
2024-08-21
Active, closed
Lorlatinib in Patients With ALK-Positive NSCLC With Brain or Leptomeningeal Metastases
NCT06282874Carcinoma, Non-Small-Cell Lung, Brain Metastases, Leptomeningeal Metastasis
Guangdong Association of Clinical Trials
Phase 4
41
Dongguan, Foshan, Guangzhou
2024-08-01
Active, closed
A Multicenter, Phase 3 Study of IBI343 Monotherapy Versus Treatment of Investigator's Choice in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, HER2-negative, Gastric or Gastroesophageal Junction Adenocarcinoma (G-HOPE-001)
NCT06238843Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Innovent Biologics (Suzhou) Co. Ltd.
Phase 3
464
Bengbu, Hefei, Lu'an, Wuhu, Beijing, Fuzhou, Lanzhou, Dongguan
2024-06-30
Active, closed
A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus
NCT06015737Cutaneous Lupus Erythematosus
AstraZeneca
Phase 3
339
Changchun, Changsha, Chengdu, Chongqing, Dongguan, Guangzhou, Heilongjiang, Jinan
2024-06-29
Recruiting
A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)
NCT06455449Polymyositis, Dermatomyositis
AstraZeneca
Phase 3
240
Beijing, Chongqing, Dongguan, Guangzhou, Hangzhou, Hengyang, Jining, Nanjing
2024-06-20
Active, closed
A Study of SKB264 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT06448312Non-Small Cell Lung Cancer
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 3
406
Baoding, Beijing, Changchun, Changsha, Chengdu, Chongqing, Dalian, Dongguan
2024-06-07
Recruiting
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
NCT06430801Crohn's Disease
Merck Sharp & Dohme LLC
Phase 3
1,200
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Dongguan, Guangzhou, Huizhou
2024-06-05
Recruiting
AMT-116 in Patients with Solid Tumors
NCT06782334Advanced Solid Tumors
Multitude Therapeutics Inc.
Phase 1/2
144
Fuzhou, Dongguan, Guangzhou, Nanning, Changsha, Hangzhou, Wenzhou
2024-05-07
Recruiting
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)
NCT05485961End Stage Kidney Disease
CSL Behring
Phase 2/3
3,110
Baotou Shi, Beijeing, Beijing, Chengdu, Dalian, Deyang Shi, Dongguan, Foshan Shi
2024-04-27
Active, closed
A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure.
NCT06268873Chronic Kidney Disease and Hypertension
AstraZeneca
Phase 3
2,554
Baotou, Beijing, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Dongguan
2024-03-29
Active, closed
A Study to Compare Uliledlimab Combined With Toripalimab, Toripalimab Monotherapy, and Pembrolizumab Monotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1- and CD73- Selected Non-Small Cell Lung Cancer
NCT06984588Non Small Cell Lung Cancer
TJ Biopharma Co., Ltd.
Phase 2/3
450
Anyang, Beijing, Bengbu, Binzhou, Changsha, Chongqing, Dongguan, Foshan
2024-03-28
Recruiting
A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma
NCT06256588Neoplasms, Head and Neck
GlaxoSmithKline
Phase 3
864
Chongqing, Baoding, Nanyang, Beijing, Changsha, Changzhou, Chengdu, Dongguan
2024-03-21
Recruiting
TPC Versus GP Induction Chemotherapy for Nasopharyngeal Carcinoma
NCT06301165Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 2
162
Guangzhou, Dongguan, Foshan, Shenzhen, Wuhan
2024-03-19
Recruiting
An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants
NCT05835310Systemic Lupus Erythematosus
AstraZeneca
Phase 3
100
Beijing, Changchun, Changsha, Dongguan, Nanjing, Shanghai, Suzhou, Wenzhou
2024-03-14
Recruiting
Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response
NCT06239727Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 3
593
Fuzhou, Xiamen, Dongguan, Foshan, Guangzhou, Shantou, Zhanjiang, Nanning
2024-03-01
Recruiting
PRevention of OsTEoporotiC FracTure 2 Pilot Study
NCT06134908Fragility Fracture
Third Affiliated Hospital, Sun Yat-Sen University
Not applicable
50
Changsha, Dongguan, Guangzhou, Hangzhou, Hefei, Shenzhen
2024-01-13
Recruiting
A Translational Study to Describe Clinical Characteristics, Biomarkers and to Identify Phenotypes and Endotypes Associated With Differential Outcomes in Chinese Population
NCT06419413Asthma
AstraZeneca
Observational
355
Chengdu, Beijing, Changsha, Dongguan, Foshan, Guangzhou, Hainan, Hohhot
2024-01-08
Active, closed
Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis
NCT06141473Multiple Sclerosis
Sanofi
Phase 3
1,655
Beijing, Changchun, Changsha, Chengdu, Chongqing, Dongguan, Fuzhou, Guangzhou
2023-12-13
Active, closed
Chronic Kidney Disease Registry Platform Study
NCT06117852Chronic Kidney Diseases
AstraZeneca
Observational
5,000
Baotou, Beijing, Changsha, Changzhou, Chengdu, Chongqing, Dongguan, Guangzhou
2023-11-28
Active, closed
Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents
NCT06120491Metastatic Castration-Sensitive Prostate Cancer
AstraZeneca
Phase 3
1,898
Beijing, Changchun, Changsha, Chengdu, Chongqing, Dongguan, Guangzhou, Guilin
2023-11-21
Active, closed
A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001)
NCT06052059Ulcerative Colitis
Merck Sharp & Dohme LLC
Phase 3
1,020
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Dongguan, Guangzhou, Huizhou
2023-10-25
By invitation
A Long-Term Extension Study to Learn More About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus
NCT06044337Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus
Biogen
Phase 3
306
Beijing, Shenzhen, Dongguan, Guangzhou, Changsha, Nanjing, Shanghai, Kunming
2023-10-03
Active, closed
A Study YL201 in Patients With Selected Advanced Solid Tumors
NCT06057922Advanced Solid Tumor
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1/2
990
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Dongguan, Foshan, Guangzhou
2023-09-22
Recruiting
A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis
NCT05995964Atopic Dermatitis
Pfizer
Phase 2
340
Beijing, Fuzhou, Dongguan, Guangzhou, Shijiazhuang, Changsha, Wuhan, Zhenjiang
2023-08-22
Active, closed
Lobectomy-First vs. Lymphadenectomy-First for Operable NSCLC (LOFTY)
NCT06577792Non Small Cell Lung Cancer
Sun Yat-sen University
Not applicable
620
Beijing, Fuzhou, Lanzhou, Dongguan, Foshan, Guangzhou, Wuhan, Nanjing
2023-08-16
Active, closed
Reduced Volume of Neck Prophylactic Irradiation in Nasopharyngeal Carcinoma
NCT05780372Nasopharyngeal Carcinoma, Radiotherapy; Complications
Sun Yat-sen University
Phase 3
474
Chongqing, Dongguan, Guangzhou, Liuzhou, Nanning, Nanchang, Hangzhou
2023-08-08
Active, closed
Cadonilimab (PD-1/CTLA-4 Bispecific Blockade) and Chemoradiotherapy in Nasopharyngeal Carcinoma (GEMSTONE)
NCT05587374Nasopharyngeal Carcinoma, Nasopharyngeal Cancer
Sun Yat-sen University
Phase 3
490
Bengbu, Hefei, Beijing, Fuzhou, Dongguan, Guangzhou, Zhongshan, Nanning
2023-08-01
Not yet open
Association of Osmotic Drugs With Clinical Outcomes in Acute Large Hemispheric Infarction
NCT05914272Stroke
Nanfang Hospital, Southern Medical University
Observational
2,592
Fuzhou, Dongguan, Guangzhou, Heyuan, Huizhou, Haikou, Changsha, Hengyang
2023-07-01
Active, closed
ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors
NCT05671510Non Small Cell Lung Cancer
OncoC4, Inc.
Phase 3
630
Hefei, Beijing, Fuzhou, Xiamen, Dongguan, Guangzhou, Nanning, Haikou
2023-06-28
Recruiting
A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)]
NCT05895786Myositis
Pfizer
Phase 3
318
Hefei, Beijing, Dongguan, Guangzhou, Cangzhou, Changsha, Nanjing, Nanchang
2023-05-20
Not yet open
Association of Prophylactic Use of Stress Ulcer Drugs and Clinical Outcomes in Patients With Acute Anterior Circulation Thrombectomy
NCT05845372Acute Ischemic Stroke
Nanfang Hospital, Southern Medical University
Observational
2,592
Fuzhou, Dongguan, Guangzhou, Heyuan, Huizhou, Haikou, Changsha, Hengyang
2023-05-01
Recruiting
Efficacy and Safety of a Half-dose Bolus of r-SAK Prior to Primary PCI in ST-elevation Myocardial Infarction
NCT05410925ST Elevation Myocardial Infarction
The First Affiliated Hospital with Nanjing Medical University
Phase 4
2,260
Nanjing, Changzhou, Chongqing, Dalian, Daqing, Dongguan, Fengcheng, Guangzhou
2023-04-08
Active, closed
A Study Assessing Repathaยฎ in Combination With Standard of Care (SOC) Compared With SOC on Major Cardiovascular Events in Chinese Participants With Atherosclerotic Cardiovascular Disease
NCT06295679Major Cardiovascular Event, Established Atherosclerotic Cardiovascular Disease
Amgen
Observational
7,000
Beijing, Chongqing, Dongguan, Foshan, Guangzhou, Huizhou, Zhuhai, Guilin
2022-12-19
Active, closed
A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough
NCT05600777Cough, Refractory Chronic Cough
Bellus Health Inc. - a GSK company
Phase 3
997
Kunshan, Leshan, รœrรผmqi, Beijing, Changsha, Chengdu, Chongqing, Dongguan
2022-12-05
Recruiting
Efficacy of Trastuzumab Deruxtecan in Metastatic Breast Cancer With Different HER2 Expression Patterns
NCT06551220Metastatic Breast Cancer
Sun Yat-sen University
Observational
800
Fuzhou, Dongguan, Foshan, Guangzhou, Shantou, Shaoguan, Shenzhen, Zhongshan
2022-10-10
Active, closed
A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus
NCT05531565Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus
Biogen
Phase 2/3
450
Beijing, Chongqing, Fuzhou, Dongguan, Guangzhou, Shenzhen, Zhongshan, Nanyang
2022-09-13
Recruiting
A Study of BL-M07D1 in Patients With Locally Advanced or Metastatic HER2-Positive/Negative Breast Cancer and Other Solid Tumors
NCT05461768Breast Cancer, Locally Advanced or Metastatic Solid Tumor
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
348
Fuzhou, Dongguan, Guangdong, Zhengzhou, Wuhan, Jinan, Hangzhou
2022-08-09
Active, closed
First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors
NCT05438329Advanced Solid Tumor
DualityBio Inc.
Phase 1/2
1,123
Bengbu, Hefei, Fuzhou, Lanzhou, Dongguan, Guangzhou, Guigang, Nanning
2022-07-19
By invitation
An Extension Study to Learn More About the Long-Term Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus
NCT05352919Systemic Lupus Erythematosus (SLE)
Biogen
Phase 3
864
Beijing, Dongguan, Guangzhou, Shenzhen, Zhongshan, Haikou, Shijiazhuang, Changsha
2022-06-10
Recruiting
Furmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNA
NCT05334277Non-small Cell Lung Cancer
Sun Yat-sen University
Phase 2
280
Changchun, Chengdu, Dongguan, Dongyang, Foshan, Guangzhou, Hangzhou, Jiangmen
2022-05-06
Active, closed
The Efficacy and Safety of Neoadjuvant Low-dose Radiotherapy Combined With Chemoimmunotherapy in Locally Advanced HNSCC
NCT05343325Head and Neck Squamous Cell Carcinoma, Neoadjuvant Treatment
Fifth Affiliated Hospital, Sun Yat-Sen University
Phase 2
25
Zhuhai, Dongguan
2022-03-09
Active, closed
Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma
NCT05097287Asthma
Sanofi
Phase 4
1,339
Beijing, Dongguan, Guangzhou, Guiyang, Hebei, Hefei, Nanchang, Nanjing
2021-12-16
Recruiting
The Efficacy And Safety Of Mitizodone Phosphate Tablets In The Treatment of Patient With Major Depressive Disorder
NCT04984512Depressive Disorder, Major
Sunshine Lake Pharma Co., Ltd.
Phase 2/3
600
Dongguan
2021-12-14
Recruiting
JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC
NCT04892173Carcinoma, Squamous Cell
Johnson & Johnson Enterprise Innovation Inc.
Phase 3
500
Bengbu, Changsha, Chengdu, Dongguan, Fuzhou, Guangzhou, Jinan, Linyi
2021-12-10
Active, closed
A Study of GNC-035, a Tetra-specific Antibody, in Participants With Locally Advanced or Metastatic Breast Cancer
NCT05160545Breast Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
36
Bengbu, Dongguan, Guangzhou, Changsha, Chengdu
2021-11-26
Recruiting
Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors
NCT05024214Solid Tumors, Non-small Cell Lung Cancer, Renal Cell Carcinoma, Hepatocellular Carcinoma
3D Medicines (Sichuan) Co., Ltd.
Phase 1/2
170
Bengbu, Beijing, Fuzhou, Xiamen, Dongguan, Guangzhou, Zhuhai, Haerbin
2021-11-15
Active, closed
A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma
NCT04974398Nasopharyngeal Carcinoma
Akeso
Phase 3
296
Hefei, Fuzhou, Xiamen, Dongguan, Guangzhou, Jiangmen, Shantou, Shenzhen
2021-08-16
Active, closed
A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus
NCT04961567Lupus Erythematosus, Systemic
Biogen
Phase 3
562
Beijing, Dongguan, Guangzhou, Shenzhen, Haikou, Changsha, Zhuzhou, Wuhan
2021-07-16
Rows per page Showing 1–100 of 103
1 2 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-china/city/dongguan

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 103 of those studies with a site in Dongguan.

How many clinical trials are recruiting in Dongguan?

52 of the 103 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 15 have not yet opened recruitment, 34 are active but closed to new participants, and 2 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Dongguan), 103 studies
PhaseStudiesRecruitingShare
Phase 3391737.9%
Phase 2211620.4%
Not applicable958.7%
Observational938.7%
Phase 4716.8%
Phase 1635.8%
Phase 1/2645.8%
Phase 2/3635.8%

Most active sponsors

Lead sponsors with the most studies (Dongguan)
Lead sponsorStudiesRecruiting
Sun Yat-sen University1410
AstraZeneca116
Akeso40
Biogen40
Nanfang Hospital, Southern Medical University40
GlaxoSmithKline33
Janssen Research & Development, LLC33
Alexion Pharmaceuticals, Inc.21
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.22
DualityBio Inc.21
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.